Abstract: The present invention relates to new sulfonamides having the formula I: ##STR1## wherein: R.sup.1 represents an alkyl, aryl or heteroaryl group; R.sup.2 is hydrogen or an alkyl, aryl or heteroaryl group; or R.sup.1 and R.sup.2 may form a ring; R.sup.3 is hydrogen or may form an oxazolidine ring together with R.sup.2, and this ring may be optionally susbtituted by one or two alkyl, aryl or heteroaryl groups at the position 2; R.sup.7 is hydrogen or alkyl; X is CH or N; Ar is a phenyl ring or a substituted phenyl ring. The invention also relates to a procedure for their preparation and to pharmaceutical and agrochemical compositions containing them. These compounds are antifungal agents.

Abstract: The present invention relates to new tetralones having the formula I: ##STR1## wherein: R.sup.1 and R.sup.2 represent hydrogen, halogen, cyano, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, pentafluoroethyl, ethynyl, trimethylsilylethynyl, C.sub.1-4 alkylcarbonylamino being the amino optionally substituted by a C.sub.1-4 alkyl group; R.sup.3 is hydrogen or C.sub.1-4 alkyl, and R.sup.4 is C.sub.1-4 alkyl, or R.sup.3 and R.sup.4 together form a C.sub.2-5 polymethylene chain; either R.sup.5 represents hydroxyl, acetoxy or formyloxy and R.sup.6 and R.sup.7 are both hydrogen, or R.sup.5 together with R.sup.6 form a carbonyl group and R.sup.7 is hydrogen, or R.sup.5 and R.sup.7 together form a bond and R.sup.6 is hydrogen; R.sup.8 is, among others, 1,2-dihydro-2-oxo-1-pyridyl, 2,3-dihydro-1-oxo-1H-isoindol-2-yl, 2-oxo-1-pyrrolidinyl, 2-oxo-1-pyperidinyl. The invention also relates to a procedure for their preparation and to pharmaceutical compositions containing them.

Abstract: The present invention relates to new tetralones having the formula I: ##STR1## wherein: R.sup.1 and R.sup.2 represent hydrogen, halogen, cyano, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, pentafluoroethyl, ethynyl, trimethylsilylethynyl, C.sub.1-4 alkylcarbonylamino being the amino optionally substituted by a C.sub.1-4 alkyl group; R.sup.3 is hydrogen or C.sub.1-4 alkyl, and R.sup.4 is C.sub.1-4 alkyl, or R.sup.3 and R.sup.4 together form a C.sub.2-5 polymethylene chain; either R.sup.5 represents hydroxyl, acetoxy or formyloxy and R.sup.6 and R.sup.7 are both hydrogen, or R.sup.5 together with R.sup.6 form a carbonyl group and R.sup.7 is hydrogen, or R.sup.5 and R.sup.7 together form a bond and R.sup.6 is hydrogen; R.sup.8 is, among others, 1,2-dihydro-2-oxo-1-pyridyl, 2,3-dihydro-1-oxo-1H-isoindol-2-yl, 2-oxo-1-pyrrolidinyl, 2-oxo-1-pyperidinyl. The invention also relates to a procedure for their preparation and to pharmaceutical compositions containing them.

Abstract: The invention relates to 1-[(2-Fluorophenyl)(4-fluorophenyl)phenylmethyl]-1H-imidazole, useful as antifungal agent.

Abstract: The present invention relates to novel 2-picolylamine derivatives of general formula I ##STR1## wherein R.sub.1 represents an alkyl or phenylalkyl radical; R.sub.2 is hydrogen, C.sub.1 -C.sub.4 acyl or C.sub.1 -C.sub.4 alkoxycarbonyl; R.sub.3 is either an electron pair, in which case t means nothing and q is 0, or R.sub.3 is hydrogen or C.sub.1 -C.sub.4, in which case t is (+) and q=1; Z is oxygen or an aminocarboniloxy group; X is O or S; m and n are 2-6; p is 0-3; A.sup.- is a pharmaceutically acceptable ion. These compounds are PAF antagonists and, consequently, useful in the treatment of the diseases in which this substance is involved.

Abstract: The present invention describes novel 2,4-disubstituted 1,3-dioxolanes having the formula I ##STR1## wherein R.sup.1 represents a long chain alkyl group; X is a covalent single bond, a carbonyl group, a carboxyl group, a carbamoyl group or a --O--P(.dbd.O)(O.sup.z)-- group; z is a negative charge (-) when q is zero, or z is an hydrogen atom when q is one; n is an integer from 2 to 10; R.sup.2, R.sup.3 and R.sup.4 are lower alkyl groups, or R.sup.2 R.sup.3 R.sup.4 N.sup.30 represents an aromatic cyclic ammonium group or R.sup.2 R.sup.3 R.sup.4 N.sup.+ represents a non-aromatic cyclic ammonium group in which two of the groups (R.sup.2, R.sup.3 or R.sup.4) form a non-aromatic ring together with the quaternary nitrogen atom; and A.sup.- is a pharmaceutically acceptable anion. These compounds are in vitro inhibitors of the platelet aggregation induced by the platelet activating factor (PAF) and, thus, useful for the treatment of the diseases in which this substance is involved.

Abstract: The present invention describes novel 2,4-disubstituted derivatives of tetrahydrofuran, having the formula I ##STR1## wherein: -X- is either an oxygen atom or a covalent single bond; --CH.sub.2 XR.sub.1 group is in the position 2 and --CH.sub.2 OR.sub.2 is in the position 4 of the tetrahydrofuran ring, or --CH.sub.2 XR.sub.1 is in position 4 and --CH.sub.2 OR.sub.2 in position 2; -R.sub.1 represents an alkyl or an alkylaminocarbonyl group; -R.sub.2 represents a group having the formula -Y-(CH.sub.2).sub.n -Q.(A.sup.-).sub.q where -Y- is a covalent single bond, a carbonyl group, a carbonyloxy group or a carbonylamino group; n is an integer 0 to 10; Q is a nitrogen containing heterocycle; q is one when Q is charged or q zero when Q is neutral; and A.sup.- is a pharmaceutically acceptable anion. These compounds are PAF antagonists and, thus, useful for the treatment of diseases in which PAF is involved.

Abstract: The present invention describes a process to obtain 4-substituted 2-alkoxytetrahydrofuran derivatives of formula I, ##STR1## wherein, --R.sub.1 represents an alkyl or phenylalkyl radical; --R.sub.2 is hydrogen, C.sub.1 -C.sub.4 -acryl or C.sub.1 -C.sub.4 -alkoxycarbonyl; --R.sub.3 is either an electron pair, in which case t means nothing and q is zero, or R.sub.3 is hydrogen or C.sub.1 -C.sub.4 alkyl, in which case t is (+) and q=1; A- is a pharmaceutically acceptable anion. These compounds are antagonists of PAF and, therefore, useful for the treatment of the diseases in which this substance is involved.

Abstract: The present invention describes novel 2,4-disubstituted 1,3-dioxolanes having the formula I ##STR1## wherein R.sup.1 represents a long chain alkyl group; X is a covalent single bond, a carbonyl group, a carboxyl group, a carbamoyl group or a --O--P(.dbd.O)(O.sup.z)-- group; z is a negative charge (-) when q is zero, or z is an hydrogen atom when q is one; n is an integer from 2 to 10; R.sup.2, R.sup.3 and R.sup.4 are lower alkyl groups, or R.sup.2 R.sup.3 R.sup.4 N.sup.+ represents an aromatic cyclic ammonium group or R.sup.2 R.sup.3 R.sup.4 N.sup.+ represents a non-aromatic cyclic ammonium group in which two of the groups (R.sup.2, R.sup.3 or R.sup.4) form a non-aromatic ring together with the quaternary nitrogen atom; and A.sup.- is a pharmaceutically acceptable anion. These compounds are in vitro inhibitors of the platelet aggregation induced by the platelet activating factor (PAF) and, thus, useful for the treatment of the diseases in which this substance is involved.